权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Further Development and Innervation of a 96 Well, 3D, Skin Model for Drug and Toxicity Testing

用于药物和毒性测试的 96 孔 3D 皮肤模型的进一步开发和神经支配

基本信息

批准号：
830238
负责人：
金额：
$ 44.6万
依托单位：
ALCYOMICS LIMITED
依托单位国家：
英国
项目类别：
Innovation Loans
财政年份：
2021
资助国家：
英国
起止时间：
2021 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=830238
关键词：
Further Development Innervation 96 Well

项目摘要

Alcyomics has developed unique non-animal non-artificial human skin explant assays (Skimune & Skimune3D) which can test for safety and efficacy of novel drugs and compounds including cosmetics. Skimune and Skimune 3D have been developed by using human skin, tissue and blood therefore giving a human response to the compounds rather than, the currently used, animal models.Alcyomics innovative assays enable the products of the pharmaceutical, chemical and cosmetic industries to reach the clinic and/or the market place quicker by early assessment of their safety profiles.Alcyomics has recently improved their service offering by the aid of Innovate UK funding by developing Skimune3D in a 96 well format. The 96 well format allows for high throughput screening saving clients both money and time and Skimune3D enables multiple dose testing and information on patient drug dosage prior to clinical trial.In this current project we aim to further exploit this model by bioprinting Skimune3D and validate the bioprinted model for safety testing, therefore creating a more standardised service offering.Alcyomics will also work with Axol Ltd to incorporate nerve cells into the model in order to enable safety testing for neural toxicity.In summary this project will increase Alcyomics' service offering and in roads into new global markets and product development.

Alcyomics开发了独特的非动物非人工人类皮肤外植体试验（Skimune & Skimune 3D），可以测试新药和化合物（包括化妆品）的安全性和有效性。Skimune和Skimune 3D是通过使用人体皮肤、组织和血液开发的，因此对化合物产生了人类反应，而不是目前使用的动物模型。Alcyomics创新的分析方法使药物产品，化学和化妆品行业，以达到临床和/Alcyomics最近在英国创新基金的帮助下改进了他们的服务，通过开发96孔格式的Skimune 3D。96孔格式允许高通量筛选，节省客户的金钱和时间，Skimune 3D可以在临床试验前进行多剂量测试和患者药物剂量信息。在当前的项目中，我们的目标是通过生物打印Skimune 3D进一步利用该模型，并验证生物打印模型的安全性测试，因此，创造了一个更标准化的服务提供。Alcyomics还将与Axol Ltd合作，将神经细胞纳入模型，以实现神经毒性的安全测试。总之，该项目将增加Alcyomics的服务提供和道路进入新的全球市场和产品开发。